Octaplas Lg (Human Plasma Protein)

Octaplas LG is used in the management of coagulation disorders within the broader category of blood‑product therapy.

• Congenital coagulation factor deficiency: Provides replacement of multiple clotting factors to control bleeding.
• Massive transfusion protocols: Supplies functional clotting activity during massive blood loss.
• Liver transplantation: Supports hemostasis by delivering a balanced mix of plasma proteins.
• Cardiac surgery: Helps maintain coagulation balance during cardiopulmonary bypass.
• Trauma‑induced coagulopathy: Contributes to rapid correction of coagulopathy in severe trauma.

• Octaplas LG contains pooled, solvent‑detergent‑treated human plasma proteins that supply a broad spectrum of functional clotting factors (including factors II, VII, IX, X and fibrinogen). By replenishing these deficient factors, it restores the physiological cascade of thrombin generation and fibrin clot formation, thereby supporting normal hemostasis in patients with acquired or congenital deficiencies.

Adverse reactions to Octaplas LG are generally related to its plasma origin and the infusion process.

Common Side Effects

• Fever or chills during infusion.
• Mild allergic skin reactions such as urticaria.
• Transient hypertension or hypotension.
• Nausea or vomiting.
• Headache.
• Mild fatigue.

Serious or Rare Side Effects

• Anaphylactic or severe allergic reaction.
• Transfusion‑related acute lung injury (TRALI).
• Volume overload leading to pulmonary edema.
• Hemolytic transfusion reaction.
• Transmission of infectious agents (extremely rare due to viral inactivation).

When using Octaplas LG, clinicians should observe several safety measures.

• Verify patient identity and indication: Ensure appropriate clinical need for plasma‑derived coagulation support.
• Monitor vital signs: Observe blood pressure, heart rate, and temperature during and after infusion.
• Assess for allergic history: Screen for prior reactions to plasma products.
• Use appropriate infusion rate: Follow institutional protocols to minimise circulatory stress.
• Maintain aseptic technique: Prevent contamination during preparation and administration.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Octaplas LG may interact with other agents that affect hemostasis or fluid balance.

Major Interactions (Avoid)

• Concurrent high‑dose anticoagulants (e.g., unfractionated heparin, direct thrombin inhibitors): increased bleeding risk.
• Massive crystalloid or colloid resuscitation: may dilute clotting factors, reducing efficacy.

Moderate Interactions (Monitor Closely)

• Antiplatelet drugs (e.g., aspirin, clopidogrel): monitor platelet function and bleeding.
• Immunosuppressants (e.g., rituximab): potential for altered immune response to plasma proteins.
• Diuretics: watch for volume overload when large volumes are infused.